|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trials-Drug |
Department of Interdisciplinary Oncology and Neurosurgery, University of South Florida College of Medicine and Neuro-Oncology Program, H. Lee Moffitt Cancer Center, Tampa, FL 33620 (S.B.); Department of Neuro-Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 (S.A.G., K.A.C., J.D.F.); Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030 (P.N.); Department of Hematology-Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322 (S.P.); Department of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA (J.B.A.); Department of Neurosurgery, Henry Ford Health System, Detroit, MI 48202 (T.M.); USA
3 Address correspondence to Steven Brem, c/o the NABTT CNS Consortium, 1650 Orleans St., Room G-93, Baltimore, MD 21231, USA (brem{at}moffitt.usf.edu).
Abstract
Penicillamine is an oral agent used to treat intracerebral copper overload in Wilson's disease. Copper is a known regulator of angiogenesis; copper reduction inhibits experimental glioma growth and invasiveness. This study examined the feasibility, safety, and efficacy of creating a copper deficiency in human glioblastoma multiforme. Forty eligible patients with newly diagnosed glioblastoma multiforme began radiation therapy (6000 cGy in 30 fractions) in conjunction with a low-copper diet and escalating doses of penicillamine. Serum copper was measured at baseline and monthly. The primary end point of this study was overall survival compared to historical controls within the NABTT CNS Consortium database. The 25 males and 15 females who were enrolled had a median age of 54 years and a median Karnofsky performance status of 90. Surgical resection was performed in 83% of these patients. Normal serum copper levels at baseline (median, 130 µg/dl; range, 50-227 µg/dl) fell to the target range of <50 µg/dl (median, 42 µg/dl; range, 12-118 µg/dl) after two months. Penicillamine-induced hypocupremia was well tolerated for months. Drug-related myelosuppression, elevated liver function tests, and skin rash rapidly reversed with copper repletion. Median survival was 11.3 months, and progression-free survival was 7.1 months. Achievement of hypocupremia did not significantly increase survival. Although serum copper was effectively reduced by diet and penicillamine, this antiangiogenesis strategy did not improve survival in patients with glioblastoma multiforme.
References
Alpern-Elran, H., and Brem, S. (1985) Angiogenesis in human brain tumors: Inhibition by copper depletion. Surg. Forum 36,498 -500.[Web of Science]
Bagley, R.G., Walter-Yohrling, J., Cao, X., Weber, W., Simons, B.,
Cook, B.P., Chartrand, S.D., Wang, C., Madden, S.L., and Teicher, B.A.
(2003) Endothelial precursor cells as a model of tumor
endothelium: Charac terization and comparison with mature endothelial cells.
Cancer Res. 63,5866
-5873.
Barker, F.G., 2nd, Chang, S.M., Larson, D.A., Sneed, P.K., Wara, W.M., Wilson, C.B., and Prados, M.D. (2001) Age and radiation response in glioblastoma multiforme. Neurosurgery 49,1288 -1298.[CrossRef][Web of Science][Medline]
Bauer, K.S., Dixon, S.C., and Figg, W.D. (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 55,1827 -1834.[CrossRef][Web of Science][Medline]
Bello, L., Carrabba, G., Giussani, C., Lucini, V., Cerutti, F.,
Scaglione, F., Landre, J., Pluderi, M., Tomei, G., Villani, R., Carroll, R.S.,
Black, P.M., and Bikfalvi, A. (2001) Low-dose chemotherapy
combined with an antiangiogenic drug reduces human glioma growth in vivo.
Cancer Res. 61,7501
-7506.
Brat, D.J., Castellano-Sanchez, A., Kaur, B., and Van Meir, E.G. (2002) Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv. Anat. Pathol. 9,24 -36.[CrossRef][Web of Science][Medline]
Brem, H., Ehrlich, P., Tsakayannis, D., and Folkman, J. (1997) Delay of wound healing by the angiogenesis inhibitor TNP-470. Surg. Forum 48,714 -716.
Brem, S. (2004) Angiogenesis and brain tumors. In: Winn, H.R. (Ed.), Youmans Neurological Surgery. Philadelphia: Saunders, pp. 771-789.
Brem, S., and Wotoczek-Obadia, M. (2001) Potential synergistic effect of copper reduction, anti-angiogenesis therapy and cytotoxic chemother apy (BCNU) in a rat brain tumor model. Proc. Am. Assoc. Cancer Res. 42,582p (abstract 3123).
Brem, S., Cotran, R., and Folkman, J. (1972) Tumor angiogenesis: A quan titative method for histologic grading. J. Natl. Cancer Inst. 48,347 -356.
Brem, S.S., Zagzag, D., Tsanaclis, A.M., Gately, S., Elkouby, M.P., and Brien, S.E. (1990a) Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic factor. Am. J. Pathol. 137,1121 -1142.[Abstract]
Brem, S., Tsanaclis, A.M., and Zagzag, D. (1990b) Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosar coma in the rat brain. Neurosurgery 26,391 -396.[CrossRef][Web of Science][Medline]
Carmeliet, P., and Jain, R.K. (2000) Angiogenesis in cancer and other dis eases. Nature 407,249 -257.[CrossRef][Medline]
Coates, R.J., Weiss, N.S., Daling, J.R., Rettmer, R.L., and
Warnick, G.R. (1989) Cancer risk in relation to serum copper
levels. Cancer Res. 49,4353
-4356.
Cox, D.R. (1972) Regression models and life tables. J. R. Stat. Soc. B. 34,187 -220.
Davis, F.G., Freels, S., Grutsch, J., Barlas, S., and Brem, S. (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J. Neurosurg. 88,1 -10.[Web of Science][Medline]
DeVore, R.F., Fehrenbacher, L., Herbst, R.S., Langer, C.J., Kelly, K., Gau dreault, J., Holmgren, E., Novotny, W.F., and Kabbinavar, F. (2000) A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV NSCLC. Proc. Am. Soc. Clin. Oncol. 19, 485a (abstract 1896).
Diez, M., Cerdan, F.J., Arroyo, M., and Balibrea, J.L. (1989) Use of copper/zinc ratio in the diagnosis of lung cancer. Cancer 63,726 -730.[CrossRef][Web of Science][Medline]
Fine, H.A., Figg, W.D., Jaeckle, K., Wen, P.Y., Kyritsis, A.P.,
Loeffler, J.S., Levin, V.A., Black, P.M., Kaplan, R., Pluda, J.M., and Yung,
W.K. (2000) Phase II trial of the antiangiogenic agent
thalidomide in patients with recurrent high-grade gliomas. J. Clin.
Oncol. 18,708
-715.
Fine, H.A., Wen, P.Y., Maher, E.A., Viscosi, E., Batchelor, T.,
Lakhani, N., Figg, W.D., Purow, B.W., and Borkowf, C.B. (2003)
Phase II trial of thalidomide and carmustine for patients with recurrent
high-grade gliomas. J. Clin. Oncol.
21,2299
-2304.
Godard, S., Getz, G., Delorenzi, M., Farmer, P., Kobayahsi, H.,
Desbaillets, I., Nozaki, M., Diserens, A.C., Hamou, M.F., Dietrich, P.Y.,
Regli, L., Janzer, R.C., Bucher, P., Stupp, R., de Tribolet, N., Domany, E.,
and Hegi, M.E. (2003) Classification of human astrocytic gliomas
on the basis of gene expression: A correlated group of genes with angiogenic
activity emerges as a strong predictor of subtypes. Cancer
Res. 63,6613
-6625.
Grossman, S.A., and Batara J. (2004) Current management of glioblastoma multiforme. Semin. Oncol. 31,635 -644.[CrossRef][Web of Science][Medline]
Grossman, S.A., Carson, K., Piantadosi, S. and Fisher, J. (2002) Survival of adults with newly diagnosed glioblastoma multiforme (GBM) treated with experimental agents and delayed radiation therapy (RT) versus experimental agents and immediate radiation: The experience of the NABTT CNS consortium. Presented at the American Society of Clini cal Oncology Annual Meeting, Orlando, Florida, May 18-21 (abstract 282). Available at: http://www.asco.org.
Hourani, B.T., and Demopoulos, H.B. (1969) Inhibition of S-91 mouse melanoma metastases and growth by D-penicillamine. Lab. Invest. 21,434 -438.[Web of Science][Medline]
Hu, G.F. (1998) Copper stimulates proliferation of human endothelial cells under culture. J. Cell Biochem. 69,326 -335.[CrossRef][Web of Science][Medline]
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350,2335 -2342.
Jain, R.K. (2001) Normalizing tumor vasculature with anti-angiogenic ther apy: A new paradigm for combination therapy. Nat. Med. 7,987 -989.[CrossRef][Web of Science][Medline]
Jong-Hon, K., Togashi, Y., Kasai, H., Hosokawa, M., and Takeichi, N. (1993) Prevention of spontaneous hepatocellular carcinoma in Long-Evans cinnamon rats with hereditary hepatitis by the administration of D-penicillamine. Hepatology 18,614 -620.[CrossRef][Web of Science][Medline]
Joyce, D.A. (1989) D-Penicillamine pharmacokinetics and pharmacody namics in man. Pharmacol. Ther. 42,405 -427.[CrossRef][Web of Science][Medline]
Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J.,
Novotny, W.F., Lieberman, G., Griffing, S., and Bergsland, E.
(2003) Phase II, randomized trial comparing bevacizumab plus
fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic
colorectal cancer. J. Clin. Oncol.
21, 60-65.
Kalbfleisch, J.D., and Prentice, R.L. (1980) The Statistical Analysis of Fail ure Time Data. New York: John Wiley & Sons.
Kaplan, E.L., and Meier, P. (1958) Nonparametric estimation from incom plete observations. J. Am. Stat. Assoc. 53,457 -481.[CrossRef][Web of Science]
Kerbel, R.S. (2001) Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results. J. Clin. Oncol. 19,45S -51S.
Khan, M.K., Miller, M.W., Taylor, J., Gill, N.K., Dick, R.D., Van Golen, K., Brew, G.J., and Merajver, S.D. (2002) Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 4, 164-170.[CrossRef][Web of Science][Medline]
Lacroix, M., Abi-Said, D., Fourney, D.R., Gokaslan, Z.L., Shi, W., DeMonte, F., Lang, F.F., McCutcheon, I.E., Hassenbusch, S.J., Holland, E., Hess, K., Michael, C., Miller, D., and Sawaya, R. (2001) A multivariate analy sis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J. Neurosurg. 95,190 -198.[Web of Science][Medline]
Linder, M.C., and Hazegh-Azam, M. (1996) Copper
biochemistry and molecular biology. Am. J. Clin. Nutr.
63,797S
-811S.
Littman, M.L., Taguchi, T., and Shimizu, Y. (1963) Acceleration of growth of sarcoma 180 with pyridoxamine and retardation with penicillamine. Proc. Soc. Exp. Biol. Med. 113,667 -674.
Marsden, C.D. (1987) Wilson's disease. Q. J. Med. 248,959 -966.
Matsubara, T., Saura, R., Hirohata, K., and Ziff, M. (1989) Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J. Clin. Invest. 83,158 -167.
Netter, P., Bannwarth, B., Pere, P., and Nicolas, A. (1987) Clinical pharma cokinetics of D-penicillamine. Clin. Pharmacokinet. 13,317 -333.[Web of Science][Medline]
Pan, Q., Kleer, C.G., van Golen, K.L., Irani, J., Bottema, K.M.,
Bias, C., De Carvalho, M., Mesri, E.A., Robins, D.M., Dick, R.D., Brewer,
G.J., and Merajver, S.D. (2002) Copper deficiency induced by
tetrathiomo lybdate suppresses tumor growth and angiogenesis.
Cancer Res. 62,4854
-4859.
Puduvalli, V.K., and Sawaya, R. (2000) Antiangiogenesis—therapeutic strategies and clinical implications for brain tumors. J. Neurooncol. 50,189 -200.[CrossRef][Medline]
Redman, B.G., Esper, P., Pan, Q., Dunn, R.L., Hussain, H.K.,
Chenevert, T., Brewer, G.J., and Merajver, S.D. (2003) Phase II
trial of tetrathiomo lybdate in patients with advanced kidney cancer.
Clin. Cancer Res. 9,1666
-1672.
Schiff, D. (1996) Pneumocystis pneumonia in brain tumor patients: Risk factors and clinical features. J. Neurooncol. 27,235 -240.[CrossRef][Medline]
Singh, G., Fries, J.F., Williams, C.A., Zatarain, E., Spitz, P., and Bloch, D.A. (1991) Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J. Rheumatol. 18,188 -194.[Web of Science][Medline]
Smith, D.B., and Gallagher, B.B. (1970) The effect of
penicillamine on sei zure threshold. The role of pyridoxine. Arch.
Neurol. 23,59
-62.
Sproull, M., Brechbiel, M., and Camphausen, K. (2003) Antiangiogenic therapy through copper chelation. Expert Opin. Ther. Targets 7,405 -409.[CrossRef][Web of Science][Medline]
Strausak, D., Mercer, J.F., Dieter, H.H., Stremmel, W., and Multhaup, G. (2001) Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res. Bull. 55,175 -185.[CrossRef][Web of Science][Medline]
Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M., Brandes, A.A., Cairncross, G., Lacombe, D., and Miri manoff, R.O. (2004) Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. J. Clin. Oncol. 22 (14S), 2 (abstract).
Takano, S., Gately, S., Engelhard, H., Tsanaclis, A.M., and Brem, S. (1994) Suramin inhibits glioma cell proliferation in vitro and in the brain. J. Neurooncol. 21,189 -201.[CrossRef][Medline]
Turecky, L., Kalina, P., Uhlikova, E., Namerova, S., and Krizko, J. (1984) Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin. Wochenschr. 62,187 -189.[CrossRef][Web of Science][Medline]
Turnlund, J.R., Scott, K.C., Peiffer, G.L., Jang, A.M., Keyes,
W.R., Keen, C.L., and Sakanashi, T.M. (1997) Copper status of
young men consum ing a low-copper diet. Am. J. Clin.
Nutr. 65,72
-78.
Weindruch, R., and Walford, R.L. (1982) Dietary
restriction in mice begin ning at 1 year of age: Effect on life-span and
spontaneous cancer inci dence. Science
215,1415
-1418.
Westphal, M., Hilt, D.C., Bortey, E., Delavault, P., Olivares, R., Warnke, P.C., Whittle, I.R., Jääskeläinen, J., and Ram, Z. (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol. 5,79 -88.[Abstract]
Williams, S.R. (1993) Nutrition and Diet Therapy, 7th ed. St. Louis: Mosby-Year Book, Inc., pp.253 -268.
Yoshida, D., Ikeda, Y., and Nakazawa, S. (1995) Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. Neurosurgery 37,287 -293.[Web of Science][Medline]
Yoshii, J., Yoshiji, H., Kuriyama, S., Ikenaka, Y., Noguchi, R., Okuda, H., Tsujinoue, H., Nakatani, T., Kishida, H., Nakae, D., Gomez, D.E., DeLorenzo, M.S, Tejera, A.M., and Fukui, H. (2001) The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int. J. Cancer 94,768 -773.[CrossRef][Web of Science][Medline]
Ziche, M., Jones, J., and Gullino, P.M. (1982) Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst. 69,475 -482.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. A. Grossman, X. Ye, M. Chamberlain, T. Mikkelsen, T. Batchelor, S. Desideri, S. Piantadosi, J. Fisher, and H. A. Fine Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial J. Clin. Oncol., September 1, 2009; 27(25): 4155 - 4161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Tye, A. G. Gilg, L. B. Tolliver, W. G. Wheeler, B. P. Toole, and B. L. Maria Hyaluronan Regulates Ceruloplasmin Production By Gliomas and Their Treatment-Resistant Multipotent Progenitors J Child Neurol, October 1, 2008; 23(10): 1221 - 1230. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Yu, J. Wong, D. B. Lovejoy, D. S. Kalinowski, and D. R. Richardson Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond Clin. Cancer Res., December 1, 2006; 12(23): 6876 - 6883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. O. Sakariassen, L. Prestegarden, J. Wang, K.-O. Skaftnesmo, R. Mahesparan, C. Molthoff, P. Sminia, E. Sundlisaeter, A. Misra, B. B. Tysnes, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells PNAS, October 31, 2006; 103(44): 16466 - 16471. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
